SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesOtherGlutathione

Glutathione

/ Tripeptide; endogenous antioxidant (not a classical peptide hormone)
TIER 2 · TranslationalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · GSH · L-γ-glutamyl-L-cysteinyl-glycine

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · CLASS · Tripeptide; endogenous antioxidant (not a classical peptide hormone)CATEGORY · Other

Widely used as an IV adjunct in alternative medicine practice. Oral bioavailability is notoriously poor. Limited rigorous RCT evidence for systemic benefits at clinically used doses.

§ B · Mechanism of action

Glutathione is an endogenous tripeptide (glutamate-cysteine-glycine) and the body's primary intracellular antioxidant. It participates in detoxification of xenobiotics and protection against oxidative stress via its cysteine sulfhydryl group.

§ C · Human clinical evidence

Intravenous glutathione is commonly administered in alternative-medicine settings for claimed detox, skin lightening, and antioxidant effects. Rigorous controlled evidence for systemic antioxidant benefits at clinically used doses is limited. Oral bioavailability is extremely poor; liposomal formulations have modest improvements.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
Compounding:
Compounding eligibility ambiguous
§ I · Notable gaps and controversies

Endogenous glutathione is rigorously studied; exogenous supplementation claims often outrun the bioavailability and mechanism data. Skin-lightening IV glutathione practice has been flagged by regulators in multiple countries.